ADP is stored in dense bodies inside blood platelets and is released upon platelet activation. ADP interacts with a family of ADP receptors found on platelets (P2Y1, P2Y12 and P2X1), leading to further platelet activation. ADP in the blood is converted to adenosine by the action of ecto-ADPases, inhibiting further platelet activation via adenosine receptors. The anti-platelet drug Plavix (clopidogrel) inhibits the P2Y12 receptor.
ADP is the end-product that results when ATP loses one of its phosphate groups located at the end of the molecule. The conversion of these two molecules plays a critical role in supplying energy for many processes of life. The deletion of one of ATP’s phosphorous bonds generates about the same amount of energy derived from human digestion of a single peanut, approximately 7.3 kilocalories per Mole of ATP. ADP can be converted, or powered back to ATP through the process of releasing the chemical energy available in food; in humans this is constantly performed via aerobic respiration in the mitochondria. Plants use photosynthetic pathways to convert and store the energy from sunlight, via conversion of ADP to ATP. Animals use the energy released in the breakdown of glucose and other molecules to convert ADP to ATP, which can then be used to fuel necessary growth and cell maintenance.
Poly (adenosine diphosphate-ribose) synthetase inhibitor 3-aminobenzamide alleviates cochlear dysfunction induced by transient ischemia
Feb 01, 2001; The present study was undertaken to determine the possible deleterious role played by poly(adenosine diphosphate-ribose)...
Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and Their Clinical Implications
Jul 01, 2012; 1. IntroductionInhibition of platelet activation has been a cornerstone of treatment of ischaemic cardiovascular disease for over...